Weight Loss & GLP-1 Stocks
5 stocks · Updated May 9, 2026
GLP-1 receptor agonist drugs represent a paradigm shift in obesity and diabetes treatment — weekly injectable medications like Ozempic and Wegovy from Novo Nordisk and Tirzepatide (Mounjaro/Zepbound) from Eli Lilly have demonstrated weight loss of 15-25% in clinical trials, far exceeding previous pharmaceutical options. The addressable market is enormous given that over 100 million Americans are obese, and emerging evidence suggests GLP-1s reduce cardiovascular events, sleep apnea, and may have applications in addiction and neurological disorders.
Get Your Daily Market Recap
TickFlow Daily delivers the top gainers, losers, and signals to your inbox every day at market close. Free.
Frequently Asked Questions
What are GLP-1 receptor agonists?
GLP-1 (glucagon-like peptide-1) agonists mimic a gut hormone that regulates appetite and blood sugar. Originally developed for diabetes, drugs like semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) produce dramatic weight loss as a secondary effect.
How large is the GLP-1 market opportunity?
Analysts estimate the GLP-1 market could reach $100-150 billion annually by 2030. Global obesity affects over 1 billion people, and if even a fraction sustain treatment, the commercial opportunity is extraordinary.
What are the barriers to GLP-1 market expansion?
Manufacturing capacity constraints (peptide synthesis is complex), high list prices ($1,000+/month), insurance coverage restrictions, and injection administration barriers all limit near-term patient uptake despite massive demand.
Which companies are competing in the GLP-1 market?
Novo Nordisk and Eli Lilly dominate with approved products. Amgen, Viking Therapeutics, Structure Therapeutics, and Roche have pipeline candidates in various stages. The oral formulation race (pills vs. injections) is a major competitive frontier.